Novo Nordisk AS (MEX:NOVOB) 3-Year Book Growth Rate : 21.10% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS 3-Year Book Growth Rate?

Novo Nordisk AS's Book Value per Share for the quarter that ended in Sep. 2024 was MXN79.36.

During the past 12 months, Novo Nordisk AS's average Book Value per Share Growth Rate was 30.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was 21.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was 17.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Novo Nordisk AS was 21.10% per year. The lowest was -2.30% per year. And the median was 7.90% per year.

Competitive Comparison of Novo Nordisk AS's 3-Year Book Growth Rate

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's 3-Year Book Growth Rate falls into.

Novo Nordisk AS 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Novo Nordisk AS (MEX:NOVOB) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Novo Nordisk AS 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NOVOB) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines